Skin signs in diabetes mellitus

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 10, 2012, Pages 1203-1211

  Behm, B ^a   Schreml, S ^a   Landthaler, M ^a   Babilas, P ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; HUMAN INSULIN; INSULIN; INSULIN LISPRO; META CRESOL; METFORMIN; ORAL ANTIDIABETIC AGENT; TOLAZAMIDE;

ACANTHOSIS NIGRICANS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANAPHYLAXIS; BACTERIAL SKIN DISEASE; BULLOUS DERMATITIS; COLLAGEN DISEASE; DERMATOMYCOSIS; DESENSITIZATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EPIDERMIS; ERYTHEMA; ERYTHEMA MULTIFORME; GANGRENE; GRANULOMA ANNULARE; HOMEOSTASIS; HUMAN; HYPERSENSITIVITY REACTION; INSULIN PUMP; INSULIN TREATMENT; INTRACELLULAR SIGNALING; KERATINOCYTE; LEUKOCYTOCLASTIC VASCULITIS; LICHEN (DISEASE); LICHEN PLANUS; LIPOATROPHY; NECROBIOSIS LIPOIDICA; ONYCHOMYCOSIS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REVIEW; SCLEREDEMA; SKIN CALCIFICATION; SKIN MANIFESTATION; STRATUM CORNEUM; VITILIGO; WOUND HEALING; XANTHOMA; YELLOW NAIL SYNDROME;

DIABETES MELLITUS; HOMEOSTASIS; HUMANS; SKIN DISEASES;

EID: 84866252028     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04475.x     Document Type: Review

References (122)

1. Shaw JE, Sicree RA, Zimmet PZ,. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
2. Perez MI, Kohn SR,. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 1994; 30: 519-531.
3. Wahid Z, Kanjee A,. Cutaneous manifestations of diabetes mellitus. J Pak Med Assoc 1998; 48: 304-305.
4. McCance DR, Dyer DG, Dunn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-2478.
5. Yamaoka H, Sasaki H, Yamasaki H, et al. Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. Diabetes Care 2010; 33: 150-155.
6. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
7. Wertheimer E, Trebicz M, Eldar T, et al. Differential roles of insulin receptor and insulin-like growth factor-1 receptor in differentiation of murine skin keratinocytes. J Invest Dermatol 2000; 115: 24-29.
8. Benoliel AM, Kahn-Perles B, Imbert J, et al. Insulin stimulates haptotactic migration of human epidermal keratinocytes through activation of NF-kappa B transcription factor. J Cell Sci 1997; 110: 2089-2097.
9. Tsao MC, Walthall BJ, Ham RG,. Clonal growth of normal human epidermal keratinocytes in a defined medium. J Cell Physiol 1982; 110: 219-229.
10. Sakai S, Endo Y, Ozawa N, et al. Characteristics of the epidermis and stratum corneum of hairless mice with experimentally induced diabetes mellitus. J Invest Dermatol 2003; 120: 79-85.
11. Seirafi H, Farsinejad K, Firooz A, et al. Biophysical characteristics of skin in diabetes: a controlled study. J Eur Acad Dermatol Venereol 2009; 23: 146-149.
12. Dissemond J, Witthoff M, Brauns TC, et al. pH values in chronic wounds. Evaluation during modern wound therapy. Hautarzt 2003; 54: 959-965.
13. Korting HC, Lukacs A, Vogt N, et al. Influence of the pH-value on the growth of Staphylococcus epidermidis, Staphylococcus aureus and Propionibacterium acnes in continuous culture. Zentralbl Hyg Umweltmed 1992; 193: 78-90.
14. Lukacs A, Korting HC, Lemke O, et al. The influence of the pH-value on the growth of Brevibacterium epidermidis in continuous culture. Acta Derm Venereol 1995; 75: 280-282.
15. Seidenari S, Giusti G,. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 1995; 75: 429-433.
16. Rippke F, Schreiner V, Doering T, et al. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus aureus. Am J Clin Dermatol 2004; 5: 217-223.
17. Kim DW, Park JY, Na GY, et al. Correlation of clinical features and skin barrier function in adolescent and adult patients with atopic dermatitis. Int J Dermatol 2006; 45: 698-701.
18. Visscher MO, Chatterjee R, Munson KA, et al. Changes in diapered and nondiapered infant skin over the first month of life. Pediatr Dermatol 2000; 17: 45-51.
19. Yosipovitch G, Tur E, Cohen O, et al. Skin surface pH in intertriginous areas in NIDDM patients. Possible correlation to candidal intertrigo. Diabetes Care 1993; 16: 560-563.
20. Mahajan S, Koranne RV, Sharma SK,. Cutaneous manifestation of diabetes mellitus. Indian J Dermatol Venereol Leprol 2003; 69: 105-108.
21. Rubin Grandis J, Branstetter BFt, Yu VL,. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis 2004; 4: 34-39.
22. Lugo-Somolinos A, Sanchez JL,. Prevalence of dermatophytosis in patients with diabetes. J Am Acad Dermatol 1992; 26: 408-410.
23. de Leon EM, Jacober SJ, Sobel JD, et al. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002; 2: 1.
24. Orasanu G, Plutzky J,. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53: S35-S42.
25. Singh N, Armstrong DG, Lipsky BA,. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293: 217-228.
26. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care 1999; 22: 1354-1360.
27. Pavicic T, Korting HC,. Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. J Dtsch Dermatol Ges 2006; 4: 935-941.
28. Chao CY, Cheing GL,. Microvascular dysfunction in diabetic foot disease and ulceration. Diabetes Metab Res Rev 2009; 25: 604-614.
29. Falanga V,. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366: 1736-1743.
30. Pradhan L, Nabzdyk C, Andersen ND, et al. Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev Mol Med 2009; 11: e2.
31. Trautner C, Haastert B, Spraul M, et al. Unchanged incidence of lower-limb amputations in a German City, 1990-1998. Diabetes Care 2001; 24: 855-859.
32. Edmonds ME, Foster AV,. Diabetic foot ulcers. BMJ 2006; 332: 407-410.
33. Kiziltan ME, Benbir G,. Clinical and nerve conduction studies in female patients with diabetic dermopathy. Acta Diabetol 2008; 45: 97-105.
34. Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 1998; 39: 101-106.
35. Morgan AJ, Schwartz RA,. Diabetic dermopathy: a subtle sign with grave implications. J Am Acad Dermatol 2008; 58: 447-451.
36. Huntley AC,. Finger pebbles: a common finding in diabetes mellitus. J Am Acad Dermatol 1986; 14: 612-617.
37. Guarneri C, Guarneri F, Borgia F, et al. Finger pebbles in a diabetic patient: Huntley's papules. Int J Dermatol 2005; 44: 755-756.
38. Hollister DS, Brodell RT,. Finger 'pebbles'. A dermatologic sign of diabetes mellitus. Postgrad Med 2000; 107: 209-210.
39. Sudy E, Urbina F, Maliqueo M, et al. Screening of glucose/insulin metabolic alterations in men with multiple skin tags on the neck. J Dtsch Dermatol Ges 2008; 6: 852-856.
40. Rasi A, Soltani-Arabshahi R, Shahbazi N,. Skin tag as a cutaneous marker for impaired carbohydrate metabolism: a case-control study. Int J Dermatol 2007; 46: 1155-1159.
41. Bito T, Kawakami C, Shimajiri S, et al. Generalized eruptive xanthoma with prominent deposition of naked chylomicrons: evidence for chylomicrons as the origin of urate-like crystals. J Cutan Pathol 2010; 37: 1161-1163.
42. Naik NS,. Eruptive xanthomas. Dermatol Online J 2001; 7: 11.
43. Renner R, Teuwen I, Harth W, et al. Eruptive xanthomas with hypertriglyceridemia. Hautarzt 2008; 59: 995-999.
44. Zadak Z,. Internist's view on skin manifestations of hyperlipidemia in diabetic patients. Vnitr Lek 2006; 52: 465-469.
45. Seyhan M, Ozcan H, Sahin I, et al. High prevalence of glucose metabolism disturbance in patients with lichen planus. Diabetes Res Clin Pract 2007; 77: 198-202.
46. Romero MA, Seoane J, Varela-Centelles P, et al. Prevalence of diabetes mellitus amongst oral lichen planus patients. Clinical and pathological characteristics. Med Oral 2002; 7: 121-129.
47. Lehman JS, Tollefson MM, Gibson LE,. Lichen planus. Int J Dermatol 2009; 48: 682-694.
48. Gonzalez-Moles MA, Scully C, Gil-Montoya JA,. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis 2008; 14: 229-243.
49. Seite S, Khemis A, Rougier A, et al. Importance of treatment of skin xerosis in diabetes. J Eur Acad Dermatol Venereol 2011; 25: 607-609.
50. Toro JR, Chu P, Yen TS, et al. Granuloma annulare and human immunodeficiency virus infection. Arch Dermatol 1999; 135: 1341-1346.
51. Goucha S, Khaled A, Kharfi M, et al. Granuloma annulare. G Ital Dermatol Venereol 2008; 143: 359-363.
52. Granel B, Serratrice J, Rey J, et al. Chronic hepatitis C virus infection associated with a generalized granuloma annulare. J Am Acad Dermatol 2000; 43: 918-919.
53. Ma HJ, Zhu WY, Yue XZ,. Generalized granuloma annulare associated with chronic hepatitis B virus infection. J Eur Acad Dermatol Venereol 2006; 20: 186-189.
54. Li A, Hogan DJ, Sanusi ID, et al. Granuloma annulare and malignant neoplasms. Am J Dermatopathol 2003; 25: 113-116.
55. Nebesio CL, Lewis C, Chuang TY,. Lack of an association between granuloma annulare and type 2 diabetes mellitus. Br J Dermatol 2002; 146: 122-124.
56. Milicic V, Ravic-Nikolic A, Jovovic-Dagovic B, et al. Generalized granuloma annulare presenting as arcuate dermal erythema. Acta Dermatovenerol Alp Panonica Adriat 2010; 19: 25-27.
57. Werchau S, Enk A, Hartmann M,. Generalized interstitial granuloma annulare-response to adalimumab. Int J Dermatol 2010; 49: 457-460.
58. Martis J, Bhat R, Nandakishore B, et al. A clinical study of vitiligo. Indian J Dermatol Venereol Leprol 2002; 68: 92-93.
59. Gould IM, Gray RS, Urbaniak SJ, et al. Vitiligo in diabetes mellitus. Br J Dermatol 1985; 113: 153-155.
60. Krause W,. Skin diseases in consequence of endocrine alterations. Aging Male 2006; 9: 81-95.
61. Savage DB, Semple RK, Chatterjee VK, et al. A clinical approach to severe insulin resistance. Endocr Dev 2007; 11: 122-132.
62. Litonjua P, Pinero-Pilona A, Aviles-Santa L, et al. Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes. Endocr Pract 2004; 10: 101-106.
63. Guran T, Turan S, Akcay T, et al. Significance of acanthosis nigricans in childhood obesity. J Paediatr Child Health 2008; 44: 338-341.
64. Maitra SK, Rowland Payne CM,. The obesity syndrome and acanthosis nigricans Acanthosis nigricans is a common cosmetic problem providing epidemiological clues to the obesity syndrome, the insulin-resistance syndrome, the thrifty metabolism, dyslipidaemia, hypertension and diabetes mellitus type II. J Cosmet Dermatol 2004; 3: 202-210.
65. Cohen O, Yaniv R, Karasik A, et al. Necrobiosis lipoidica and diabetic control revisited. Med Hypotheses 1996; 46: 348-350.
66. Gottrup F, Karlsmark T,. Leg ulcers: uncommon presentations. Clin Dermatol 2005; 23: 601-611.
67. Muller SA, Winkelmann RK,. Necrobiosis lipoidica diabeticorum. A clinical and pathological investigation of 171 cases. Arch Dermatol 1966; 93: 272-81.
68. Jiquan S, Khalaf AT, Jinquan T, et al. Necrobiosis lipoidica: a case with histopathological findings revealed asteroid bodies and was successfully treated with dipyridamole plus intralesional triamcinolone. J Dermatolog Treat 2008; 19: 54-57.
69. Lim C, Tschuchnigg M, Lim J,. Squamous cell carcinoma arising in an area of long-standing necrobiosis lipoidica. J Cutan Pathol 2006; 33: 581-583.
70. Clayton TH, Harrison PV,. Successful treatment of chronic ulcerated necrobiosis lipoidica with 0.1% topical tacrolimus ointment. Br J Dermatol 2005; 152: 581-582.
71. Narbutt J, Torzecka JD, Sysa-Jedrzejowska A, et al. Long-term results of topical PUVA in necrobiosis lipoidica. Clin Exp Dermatol 2006; 31: 65-67.
72. Darvay A, Acland KM, Russell-Jones R,. Persistent ulcerated necrobiosis lipoidica responding to treatment with cyclosporin. Br J Dermatol 1999; 141: 725-727.
73. Kreuter A, Knierim C, Stucker M, et al. Fumaric acid esters in necrobiosis lipoidica: results of a prospective non-controlled study. Br J Dermatol 2005; 153: 802-807.
74. Suarez-Amor O, Perez-Bustillo A, Ruiz-Gonzalez I, et al. Necrobiosis lipoidica therapy with biologicals: an ulcerated case responding to etanercept and a review of the literature. Dermatology 2010; 221: 117-121.
75. Buschke A,. Vorstellung eines Falles von Sklerödem vor der Berliner Gesellschaft für Dermatologie. Arch Dermatol Syph 1900; 52: 383.
76. Beers WH, Ince A, Moore TL,. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 2006; 35: 355-359.
77. Meguerditchian C, Jacquet P, Beliard S, et al. Scleredema adultorum of Buschke: an under recognized skin complication of diabetes. Diabetes Metab 2006; 32: 481-484.
78. Lewerenz V, Ruzicka T,. Scleredema adultorum associated with type 2 diabetes mellitus: a report of three cases. J Eur Acad Dermatol Venereol 2007; 21: 560-561.
79. Krasagakis K, Hettmannsperger U, Trautmann C, et al. Persistent scleredema of Buschke in a diabetic: improvement with high-dose penicillin. Br J Dermatol 1996; 134: 597-598.
80. Eberlein-Konig B, Vogel M, Katzer K, et al. Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol 2005; 19: 203-204.
81. Hager CM, Sobhi HA, Hunzelmann N, et al. Bath-PUVA therapy in three patients with scleredema adultorum. J Am Acad Dermatol 1998; 38: 240-242.
82. Bowen AR, Smith L, Zone JJ,. Scleredema adultorum of Buschke treated with radiation. Arch Dermatol 2003; 139: 780-784.
83. Konemann S, Hesselmann S, Bolling T, et al. Radiotherapy of benign diseases-scleredema adultorum Buschke. Strahlenther Onkol 2004; 180: 811-814.
84. Anand KP, Kashyap AS,. Bullosis diabeticorum. Postgrad Med J 2004; 80: 354.
85. El Fekih N, Zeglaoui F, Sioud A, et al. [Bullosis diabeticorum: report of ten cases]. Tunis Med 2009; 87: 747-749.
86. Basarab T, Munn SE, McGrath J, et al. Bullosis diabeticorum. A case report and literature review. Clin Exp Dermatol 1995; 20: 218-220.
87. Lopez PR, Leicht S, Sigmon JR, et al. Bullosis diabeticorum associated with a prediabetic state. South Med J 2009; 102: 643-644.
88. Toonstra J,. Bullosis diabeticorum. Report of a case with a review of the literature. J Am Acad Dermatol 1985; 13: 799-805.
89. Larsen K, Jensen T, Karlsmark T, et al. Incidence of bullosis diabeticorum-a controversial cause of chronic foot ulceration. Int Wound J 2008; 5: 591-596.
90. Saray Y, Seckin D, Bilezikci B,. Acquired perforating dermatosis: clinicopathological features in 22 cases. J Eur Acad Dermatol Venereol 2006; 20: 679-688.
91. Basak PY, Turkmen C,. Acquired reactive perforating collagenosis. Eur J Dermatol 2001; 11: 466-468.
92. Doshi SN, Levy ML, Markus R,. Koebnerization of reactive perforating collagenosis induced by laser hair removal. Lasers Surg Med 2003; 32: 177-179.
93. Matthes T, Hagedorn M,. Acquired reactive perforating collagenosis after curettage of seborrheic keratoses. J Dtsch Dermatol Ges 2004; 2: 200-202.
94. Karpouzis A, Giatromanolaki A, Sivridis E, et al. Acquired reactive perforating collagenosis: current status. J Dermatol 2010; 37: 585-592.
95. Patterson JW,. The perforating disorders. J Am Acad Dermatol 1984; 10: 561-581.
96. Schmults CA,. Acquired reactive perforating collagenosis. Dermatol Online J 2002; 8: 8.
97. Hoque SR, Ameen M, Holden CA,. Acquired reactive perforating collagenosis: four patients with a giant variant treated with allopurinol. Br J Dermatol 2006; 154: 759-762.
98. Munch M, Balslev E, Jemec GB,. Treatment of perforating collagenosis of diabetes and renal failure with allopurinol. Clin Exp Dermatol 2000; 25: 615-616.
99. Sueki H, Nozaki S, Numazawa S, et al. Effect of non-enzymatic glycosylation and heating on browning of human stratum corneum and nail. Dermatologica 1991; 183: 197-202.
100. Nikoleishvili LR, Kurashvili RB, Virsaladze DK, et al. Characteristic changes of skin and its accessories in type 2 diabetes mellitus. Georgian Med News 2006; 131: 43-46.
101. Beltrand J, Guilmin-Crepon S, Castanet M, et al. Insulin allergy and extensive lipoatrophy in child with type 1 diabetes. Horm Res 2006; 65: 253-260.
102. Reeves WG, Allen BR, Tattersall RB,. Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Br Med J 1980; 280: 1500-1503.
103. Richardson T, Kerr D,. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4: 661-667.
104. McNally PG, Jowett NI, Kurinczuk JJ, et al. Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J 1988; 64: 850-853.
105. Young RJ, Hannan WJ, Frier BM, et al. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 1984; 7: 479-480.
106. Naf S, Esmatjes E, Recasens M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002; 25: 634-635.
107. Kumar D,. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997; 20: 1357-1359.
108. Ullman HR, Dasgupta A, Recht M, et al. CT of dystrophic calcification in subcutaneous soft tissues secondary to chronic insulin injection. J Comput Assist Tomogr 1995; 19: 657-659.
109. Clerx V, Van Den Keybus C, Kochuyt A, et al. Drug intolerance reaction to insulin therapy caused by metacresol. Contact Dermatitis 2003; 48: 162-163.
110. Wonders J, Eekhoff EM, Heine R, et al. Insulin allergy: background, diagnosis and treatment. Ned Tijdschr Geneeskd 2005; 149: 2783-2788.
111. Koca R, Altinyazar HC, Yenidunya S, et al. Psoriasiform drug eruption associated with metformin hydrochloride: a case report. Dermatol Online J 2003; 9: 11.
112. Ben Salem C, Hmouda H, Slim R, et al. Rare case of metformin-induced leukocytoclastic vasculitis. Ann Pharmacother 2006; 40: 1685-1687.
113. Wiwanitkit V,. Metformin allergy. Indian J Pharmacol 2011; 43: 216-217.
114. Burger DE, Goyal S,. Erythema multiforme from metformin. Ann Pharmacother 2004; 38: 1537.
115. Goldberg I, Sasson A, Gat A, et al. Pemphigus vulgaris triggered by glibenclamide and cilazapril. Acta Dermatovenerol Croat 2005; 13: 153-155.
116. Goh CL,. Psoriasiform drug eruption due to glibenclamide. Australas J Dermatol 1987; 28: 30-32.
117. Paterson AJ, Lamey PJ, Lewis MA, et al. Pemphigus vulgaris precipitated by glibenclamide therapy. J Oral Pathol Med 1993; 22: 92-95.
118. Fujii S, Nakashima T, Kaneko T,. Glibenclamide-induced photosensitivity in a diabetic patient with erythropoietic protoporphyria. Am J Hematol 1995; 50: 223.
119. Wu CS, Chang WY, Lan CC, et al. Acute generalized exanthematous pustulosis possibly induced by acarbose. Int J Dermatol 2008; 47: 1313-1315.
120. Kono T, Hayami M, Kobayashi H, et al. Acarbose-induced generalised erythema multiforme. Lancet 1999; 354: 396-397.
121. Franz CB, Massullo RE, Welton WA,. Lichenoid drug eruption from chlorpropamide and tolazamide. J Am Acad Dermatol 1990; 22: 128-129.
122. Noakes R,. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride. Australas J Dermatol 2003; 44: 302-303.